(NEOG) Neogen - Ratings and Ratios
Diagnostics, Kits, Culture, Reagents, Consumables
NEOG EPS (Earnings per Share)
NEOG Revenue
Description: NEOG Neogen
Neogen Corporation is a US-based company operating in the Health Care Supplies sub-industry, with its common stock listed on NASDAQ under the ticker symbol NEOG.
The companys current market capitalization stands at approximately $1.1 billion, indicating a significant presence in the market. However, the negative Return on Equity (ROE) of -41.46% raises concerns about its profitability and ability to generate returns for shareholders.
The forward Price-to-Earnings (P/E) ratio of 16.00 suggests that investors have certain expectations for the companys future earnings growth. To meet these expectations, Neogen will need to demonstrate improved profitability and a robust growth trajectory.
Key economic drivers for Neogen Corporation likely include demand for healthcare supplies, trends in the diagnostics and food safety testing markets, and the overall performance of the healthcare industry. To gauge the companys performance, investors may monitor KPIs such as revenue growth, gross margin expansion, and operating cash flow generation.
A critical analysis of Neogens quarterly tax provision is essential to understanding its financial health and identifying potential areas for improvement. A thorough examination of the tax provision can reveal insights into the companys effective tax rate, potential tax liabilities, and the impact of tax-related factors on its bottom line.
To drive growth and improve profitability, Neogen may need to focus on strategic initiatives such as expanding its product portfolio, enhancing operational efficiency, and investing in research and development to stay competitive in the healthcare supplies market.
NEOG Stock Overview
| Market Cap in USD | 1,245m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 1989-08-23 |
NEOG Stock Ratings
| Growth Rating | -89.1% |
| Fundamental | 36.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -71.8% |
| Analyst Rating | 4.33 of 5 |
NEOG Dividends
Currently no dividends paidNEOG Growth Ratios
| Growth Correlation 3m | 61.2% |
| Growth Correlation 12m | -91.3% |
| Growth Correlation 5y | -89.5% |
| CAGR 5y | -30.10% |
| CAGR/Max DD 3y | -0.37 |
| CAGR/Mean DD 3y | -0.96 |
| Sharpe Ratio 12m | -1.02 |
| Alpha | -83.01 |
| Beta | 0.890 |
| Volatility | 42.23% |
| Current Volume | 4161.9k |
| Average Volume 20d | 4988.6k |
| Stop Loss | 5.1 (-6.8%) |
| Signal | -1.02 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-1.09b TTM) > 0 and > 6% of Revenue (6% = 53.7m TTM) |
| FCFTA 0.00 (>2.0%) and ΔFCFTA 1.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 45.04% (prev 47.06%; Δ -2.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 58.2m > Net Income -1.09b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (217.0m) change vs 12m ago 0.20% (target <= -2.0% for YES) |
| Gross Margin 47.10% (prev 50.19%; Δ -3.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 22.29% (prev 20.16%; Δ 2.13pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -14.82 (EBITDA TTM -964.9m / Interest Expense TTM 71.6m) >= 6 (WARN >= 3) |
Altman Z'' -1.92
| (A) 0.12 = (Total Current Assets 576.9m - Total Current Liabilities 174.0m) / Total Assets 3.44b |
| (B) -0.16 = Retained Earnings (Balance) -536.4m / Total Assets 3.44b |
| (C) -0.26 = EBIT TTM -1.06b / Avg Total Assets 4.01b |
| (D) -0.39 = Book Value of Equity -530.6m / Total Liabilities 1.37b |
| Total Rating: -1.92 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.54
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield 0.46% = 0.23 |
| 3. FCF Margin 1.03% = 0.26 |
| 4. Debt/Equity 0.43 = 2.41 |
| 5. Debt/Ebitda -0.93 = -2.50 |
| 6. ROIC - WACC -36.15% = -12.50 |
| 7. RoE -41.46% = -2.50 |
| 8. Rev. Trend 42.99% = 2.15 |
| 9. Rev. CAGR 21.37% = 2.50 |
| 10. EPS Trend 39.59% = 0.99 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of NEOG shares?
Over the past week, the price has changed by -3.36%, over one month by +0.74%, over three months by -3.01% and over the past year by -66.52%.
Is Neogen a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NEOG is around 3.33 USD . This means that NEOG is currently overvalued and has a potential downside of -39.12%.
Is NEOG a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NEOG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.5 | 18.8% |
| Analysts Target Price | 6.5 | 18.8% |
| ValueRay Target Price | 3.6 | -33.6% |
Last update: 2025-09-11 04:45
NEOG Fundamental Data Overview
CCE Cash And Equivalents = 129.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 16.0
P/S = 1.3911
P/B = 0.6009
P/EG = 0.6575
Beta = 1.846
Revenue TTM = 894.7m USD
EBIT TTM = -1.06b USD
EBITDA TTM = -964.9m USD
Long Term Debt = 874.8m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 894.1m USD (Calculated: Short Term 19.3m + Long Term 874.8m)
Net Debt = -109.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.01b USD (1.24b + Debt 894.1m - CCE 129.0m)
Interest Coverage Ratio = -14.82 (Ebit TTM -1.06b / Interest Expense TTM 71.6m)
FCF Yield = 0.46% (FCF TTM 9.24m / Enterprise Value 2.01b)
FCF Margin = 1.03% (FCF TTM 9.24m / Revenue TTM 894.7m)
Net Margin = -122.1% (Net Income TTM -1.09b / Revenue TTM 894.7m)
Gross Margin = 47.10% ((Revenue TTM 894.7m - Cost of Revenue TTM 473.3m) / Revenue TTM)
Tobins Q-Ratio = -3.79 (set to none) (Enterprise Value 2.01b / Book Value Of Equity -530.6m)
Interest Expense / Debt = 1.92% (Interest Expense 17.1m / Debt 894.1m)
Taxrate = 21.0% (US default)
NOPAT = -1.06b (EBIT -1.06b, no tax applied on loss)
Current Ratio = 3.32 (Total Current Assets 576.9m / Total Current Liabilities 174.0m)
Debt / Equity = 0.43 (Debt 894.1m / last Quarter total Stockholder Equity 2.07b)
Debt / EBITDA = -0.93 (Net Debt -109.7m / EBITDA -964.9m)
Debt / FCF = 96.78 (Debt 894.1m / FCF TTM 9.24m)
Total Stockholder Equity = 2.63b (last 4 quarters mean)
RoA = -31.71% (Net Income -1.09b, Total Assets 3.44b )
RoE = -41.46% (Net Income TTM -1.09b / Total Stockholder Equity 2.63b)
RoCE = -30.25% (Ebit -1.06b / (Equity 2.63b + L.T.Debt 874.8m))
RoIC = -30.11% (NOPAT -1.06b / Invested Capital 3.52b)
WACC = 6.04% (E(1.24b)/V(2.14b) * Re(9.29%)) + (D(894.1m)/V(2.14b) * Rd(1.92%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 51.52 | Cagr: 6.56%
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 65.03% ; FCFE base≈9.24m ; Y1≈6.07m ; Y5≈2.77m
Fair Price DCF = 0.21 (DCF Value 44.8m / Shares Outstanding 217.2m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 42.99 | Revenue CAGR: 21.37%
Rev Growth-of-Growth: -20.98
EPS Correlation: 39.59 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -114.0
Additional Sources for NEOG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle